Anika Therapeutics (ANIK) Gross Profit (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Gross Profit data on file, last reported at $19.0 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 29.4% year-over-year to $19.0 million in Q1 2026; TTM through Mar 2026 was $68.1 million, a 4.99% decrease from a year earlier, with the FY2025 full-year figure at $63.8 million, down 16.04% from the prior year.
• Gross Profit for Q1 2026 stood at $19.0 million, down from $19.2 million in the prior quarter.
• Over the last five years, Gross Profit for ANIK reached as high as $29.0 million in Q2 2023 and fell as low as $3.8 million in Q4 2022.
• Historically, Gross Profit has averaged $18.5 million across 5 years, with a median of $19.2 million in 2025.
• Across the five-year window, Gross Profit slumped 79.18% in 2022 and soared 196.66% in 2024, its largest moves.
• Year by year, Gross Profit stood at $3.8 million in 2022, then jumped by 52.93% to $5.8 million in 2023, then soared by 196.66% to $17.1 million in 2024, then advanced by 11.99% to $19.2 million in 2025, then fell by 0.95% to $19.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $19.0 million in Q1 2026, $19.2 million in Q4 2025, and $15.6 million in Q3 2025.